Aurinia Pharmaceuticals AUPH EBITDA
EBITDA at other companies
Other financials
Where this comes from
Calculated from Aurinia Pharmaceuticals’s reported figures.
The official record: Aurinia Pharmaceuticals’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Aurinia Pharmaceuticals's ebitda.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI

Claude
Questions, answered.
- What is Aurinia Pharmaceuticals's EBITDA?
- Aurinia Pharmaceuticals (AUPH) reported EBITDA of $46.24M in Q1 2026.
- How has Aurinia Pharmaceuticals's EBITDA changed year-over-year?
- Aurinia Pharmaceuticals's EBITDA increased by 73.2% year-over-year, from $26.7M to $46.24M.
- What is the long-term trend for Aurinia Pharmaceuticals's EBITDA?
- Over 4 years (2021 to 2025), Aurinia Pharmaceuticals's EBITDA has grown at a -8.6% compound annual growth rate (CAGR), from -$177.97M to $124.36M.
- What does EBITDA mean?
- Earnings before interest, taxes, depreciation, and amortization — EBIT plus the D&A add-back from the cash-flow statement (EBITDA = EBIT + D&A). A proxy for cash earnings that strips out financing, tax, and non-cash charges.